COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING

被引：0
|
作者：
Hori, M. [1 ]
Tanahashi, N. [2 ]
Akiyama, S. [3 ]
Kiyabu, G. [4 ]
Dorey, J. [5 ]
Goto, R. [6 ]
机构：
[1] Osaka Int Canc Inst, Osaka, Japan
[2] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[3] Bayer Yakuhin Ltd, Tokyo, Japan
[4] Creat Ceut, Tokyo, Japan
[5] Creat Ceut, Paris, France
[6] Keio Univ, Yokohama, Kanagawa, Japan
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV73
引用
收藏
页码：S554 / S555
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation in the Japanese healthcare setting
    Hori, Masatsugu
    Tanahashi, Norio
    Akiyama, Sayako
    Kiyabu, Grace
    Dorey, Julie
    Goto, Rei
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (03) : 252 - 261
  • [2] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [3] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    [J]. Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [4] Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
    Joris Kleintjens
    Xiao Li
    Steven Simoens
    Vincent Thijs
    Marnix Goethals
    Ernst R. Rietzschel
    Yumi Asukai
    Ömer Saka
    Thomas Evers
    Petra Faes
    Stefaan Vansieleghem
    Mimi De Ruyck
    [J]. PharmacoEconomics, 2013, 31 : 909 - 918
  • [5] Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
    Kleintjens, Joris
    Li, Xiao
    Simoens, Steven
    Thijs, Vincent
    Goethals, Marnix
    Rietzschel, Ernst R.
    Asukai, Yumi
    Saka, Omer
    Evers, Thomas
    Faes, Petra
    Vansieleghem, Stefaan
    De Ruyck, Mimi
    [J]. PHARMACOECONOMICS, 2013, 31 (10) : 909 - 918
  • [6] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (02) : 149 - 154
  • [7] Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    [J]. Journal of Thrombosis and Thrombolysis, 2015, 39 : 149 - 154
  • [8] COST-EFFECTIVENESS OF RIVAROXABAN IN THE PREVENTION OF STROKE IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN ITALY
    Capri, S.
    Veneziano, M.
    Ricciardi, W. G.
    D'Ausilio, A.
    Pedone, M. P.
    Bianchi, C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A525 - A526
  • [9] COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION IN THE GUANGDONG HEALTHCARE SETTING IN CHINA
    Zhou, J.
    Huang, B. Y.
    Yang, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A653 - A653
  • [10] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
12345